Efficacy of Metformin plus Sodium Glucose Transporter-2 inhibitors (SGLT-2i) in Obese Type 2
Abstract
Objective: To determine the efficacy of Metformin plus SGLT2 inhibitors in type 2 obese diabetic patients attending OPD at Liaquat University Hospital Hyderabad / Jamshoro.Methods
This quasi-experimental study was undertaken in the out-patient department of Liaquat University Hospital Hyderabad / Jamshoro from June 10th, 2022 to February 10th, 2023.All patients with type 2 DM for at least 8 months duration, already taking metformin with BMI ≥30kg/m2 and age limit from 30-55 years, of either gender were consecutively enrolled. SGLT2 inhibitors 10 mg once daily was added to Tab Metformin 500mg. The reduction in HbA1c of at least ≥0.5% from the baseline, at 6 months was considered as efficacy.Results
Of 114 patients, the mean age was 45.24 ±4.89 years. There were 76 (66.7%) males and 38 (33.3%) females. The mean weight, height, and BMI of the patients were 87.51 ±9.33 kg, 1.54 ±0.06 m, and 32.04 ±2.64 kg/m2 respectively. The mean pre and post HbA1c level were 9.78 ±1.43 and 8.73 ±1.39 respectively. 70 patients (61.4%) have shown reduction of HbA1c from 0.5 to 1.5% in 6 months, p-value was 0.002 significant in those with highA1c. Weight reduction was significant in both groups, BMI <30 p value 0.03 and in those BMI >30, p value was 0.02.Conclusion
The efficacy of Metformin plus SGLT2 inhibitors was found in more than half of the type 2 obese diabetic patients attending OPD at Liaquat University Hospital Hyderabad / Jamshoro.Keywords:
Efficacy, Metformin, SGLT2 Inhibitors, Type 2 Diabetes, ObesityPublished
2024/08/30
Issue
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com